Drug profile · INN
avibactam sodium
AVYCAZ
avibactam sodium (AVYCAZ) is a bacterial beta-lactamase tem inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — avibactam sodium
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
avibactam sodium (AVYCAZ) is a bacterial beta-lactamase tem inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial beta-lactamase TEM inhibitor
Primary target: Beta-lactamase TEM
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is avibactam sodium?
avibactam sodium (AVYCAZ) is a bacterial beta-lactamase tem inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for avibactam sodium?
AVYCAZ is a marketed brand name for avibactam sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of avibactam sodium?
avibactam sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.